The CD95 (Fas/APO-1) system regulates a number of physiological and pathological processes of cell death. The ligand for CD95 induces apoptosis in sensitive target cells by interacting with a transmembrane cell surface CD95 receptor. We previously reported that the recombinant adenovirus-mediated transfer of the wildtype p53 gene caused apoptotic cell death in a variety of human cancer cells. To better understand the mechanism responsible for this cell death signaling, we have investigated the potential involvement of the CD95 receptor/ligand system in p53-mediated apoptosis. The transient expression of the wild-type p53 gene upregulated the CD95 ligand mRNA as well as protein expression in H1299 human lung cancer cells de®cient for p53 and in DLD-1 and SW620 human colon cancer cells with mutated p53, all of which constitutively expressed CD95 receptor as shown by a¯ow cytometric analysis, and induced rapid apoptotic cell death as early as 24 h after gene transfer. However, the sensitivity to the cytolytic eect of agonistic anti-CD95 antibody (CH11) varied among these cell lines: CH11 induced apoptosis in H1299 cells, but not in DLD-1 and SW620 cells despite their abundant CD95 receptor expression, suggesting that the CD95 receptors on DLD-1 and SW620 cells might be inactivated. In addition, an antagonistic anti-CD95 ligand antibody (4H9) that interfered with the CD95-receptor-ligand interaction partially reduced the apoptosis induced by the wild-type p53 gene transfer in H1299 cells, whereas apoptosis of DLD-1 and SW620 cells occurred in the presence of 4H9. Taken together, these ®ndings led us to conclude that the CD95 receptor/ligand system is dierentially involved in p53-mediated apoptosis, suggesting that the restoration of the wild-type p53 function may mediate apoptosis through CD95 receptor/ligand interactions as well as an alternative pathway.
Introduction
Apoptosis is a physiological mechanism de®ned by morphologic alterations such as the condensation and margination of chromatin concomitant with cell shrinkage that are clearly distinct from necrosis (Kerr et al., 1972; Thompson, 1995) . These changes are followed by a characteristic intranucleosomal DNA fragmentation resulting from the cleavage of nuclear DNA. It is now accepted that apoptosis is a genedirected process and associated with several messenger systems that regulate this process either positively or negatively. The tumor suppressor p53 gene has been shown to be a key molecule that connects between nuclear DNA damage and the complex cellular apparatus that is responsible for apoptotic cell death (Levine, 1997) . Numerous studies have shown that p53 protein activates the transcription of a number of genes such as p21 waf1/cip1 (Harper et al., 1993; Xiong et al., 1993; El-Deiry et al., 1993) , bax (Selvakumaran et al., 1994; Miyashita and Reed, 1995) , mdm2 (Momand et al., 1992) , insulin-like growth factor-binding protein (IGF-BP) (Buckbinder et al., 1995) and CD95 (Fas/ APO-1) (Owen-Schaub et al., 1995) . We previously reported that the overexpression of the wild-type p53 (wt-p53) gene by recombinant, replication-de®cient viral vectors induced apoptosis in a variety of human cancer cells diering their p53 status (Fujiwara et al., 1993; Kagawa et al., 1997) . The elucidation of the molecular mechanism of p53-mediated apoptosis would provide insights into the mode of action of DNAdamaging conventional cancer therapies, including chemotherapeutic agents and ionizing radiation, as well as the development of novel cancer gene therapies using the wt-p53 gene.
CD95, also known as Fas or APO-1, is a type I transmembrane cell surface receptor that belongs to the nerve growth factor/tumor necrosis factor receptor superfamily (Itoh et al., 1991; Oehm et al., 1992) . The ligation of CD95 by the CD95 ligand (CD95-L) or by an agonistic anti-CD95 antibody triggers a series of events inside the cell that leads to the rapid induction of apoptosis (Trauth et al., 1989; Watanabe-Fukunaga et al., 1992; Suda et al., 1993) . CD95 has been shown to be expressed on a variety of normal and neoplastic cells, and to mediate apoptosis during developmental cell elimination and in the regulation of immune system and during cytotoxic T cell-mediated cytotoxi-city (Lowin et al., 1994; Kagi et al., 1994; Berk, 1995) . Recent studies have demonstrated that CD95-L is expressed in a wide range of normal tissues as well as tumor cells, including human melanoma (Hahne et al., 1996) , hepatocellular carcinoma (Strand et al., 1996) , colon cancer (O'Connel et al., 1996) and lung cancer (Niehans et al., 1997) . Moreover, conventional chemotherapeutic agents such as doxorubicin, bleomycin, cisplatinum, and VP-16 enhance the expression of CD95-L mRNA in human tumor cells, indicating that drug-induced apoptosis may be mediated via the CD95 receptor/ligand system (Muller et al., 1997) . These observations suggest that the CD95 receptor/ligand system may also play a critical role in the apoptosis induced by a wt-p53 gene transfer.
In the present study, we found that adenovirusmediated wt-p53 transduction rapidly induces apoptosis in the CD95-expressing human cancer cell lines, following the transient up-regulation of CD95 levels. However, the susceptibility to CD95 stimulation was not uniformly correlated with the expression of CD95 protein in these tumor cells, and the inhibition of CD95 signal transduction could partially block the p53-mediated apoptosis in only one of the three cell lines tested. Thus, the CD95 receptor/ligand interaction may dierentially contribute to the apoptosis induced by wt-p53 gene transfer in human cancer cells.
Results

Eciency of adenovirus-mediated wt-p53 transduction on human cancer cell lines
A replication-de®cient adenovirus vector carrying a wtp53 gene under the control of the cytomegalovirus (CMV) promoter (Ad5CMVp53) was generated to achieve ecient gene transfer into human cancer cells. Monolayer cultures of p53-de®cient H1299 human nonsmall lung cancer (NSCLC) cells and mutant p53-expressing DLD-1 and SW620 human colorectal cancer cells were infected with either Ad5RSVLuc or Ad5CMVp53 at a multiplicity of infection (MOI) of 50. A reverse transcription-polymerase chain reaction (RT ± PCR) analysis using a sense primer for the CMV promoter and an antisense primer located within p53 exon 3 was performed 24 h after the infection. A CMV/ p53 segment was detected in H1299, DLD-1, and SW620 cells transduced with wt-p53, whereas it was not present in the parental or Ad5RSVLuc-infected cells ( Figure 1a ). a b Figure 1 (a) Detection of adenovirally transduced wt-p53 gene expression in H1299, DLD-1, and SW620 human cancer cell lines by RT ± PCR analysis. Cells were infected with either Ad5CMVp53 or Ad5RSVLuc vectors at a MOI of 50. First-strand DNA generated from RNA was ampli®ed using CMV promoter/p53 exon 3 primers or GAPDH primers. The PCR products were visualized on an ethidium bromide gel. (b) Immunohistochemistry of Mock-infected and Ad5CMVp53-infected cells. H1299 and DLD-1 cells were stained with anti-p53 and anti-p21
WAF1 antibodies 24 h after infection WAF1 expression was also evident in most cells transduced with Ad5CMVp53 (Figure 1b) .
Induction of apoptosis by Ad5CMVp53 infection in human cancer cell lines
We next assessed the eects of Ad5CMVp53 infection on the cell cycle by¯ow cytometry analysis. H1299, DLD-1, and SW620 cells were infected with Ad5CMVp53 at a MOI of 50, harvested at 24 and 36 h post-infection, and then assayed for DNA content by propidium iodine staining. Whereas the cells infected with control Ad5RSVLuc showed no speci®c pattern in the cell cycle distribution (data not shown), the Ad5CMVp53-infected H1299, DLD-1, and SW620 cells exhibited a DNA content less than the diploid G0/G1 peak, indicating apoptosis-speci®c nuclear fragmentation, as early as 24 h after infection (Figure 2 ). This fraction was even more pronounced 36 h after the wt-p53 transduction. Consistent with the results of the¯ow cytometry analysis, a rapid loss of cell viability due to massive cell death, as evidenced by¯oating, highly light-refractile cells, was observed in the Ad5CMVp53-infected cells, while the Ad5RSVLuc-infected cells retained both a morphology and a growth rate similar to those of uninfected cells (data not shown).
Constitutive expression of the CD95 receptor in H1299, DLD-1 and SW620 cells
To de®ne the cell surface expression of the CD95 receptor, we examined three cell lines by¯ow cytometry. As shown in Figure 3 , H1299, DLD-1, and SW620 cells expressed a large amount of the surface CD95 receptor in 84.39, 90.43, and 42.41% of the cells, respectively. The levels of expression on these cell lines were comparable to that of WR19L-12a, a murine T-cell leukemia cell line transfected with human CD95 gene (data not shown). Parental WR19L cells negative for CD95 were used as a negative control. We and others previously demonstrated the wt-p53-mediated up-regulation of CD95 in tumor cell lines (Owen-Schaub et al., 1995) . The levels of CD95 expression were slightly enhanced to 96.65% in H1299 cells, to 96.78% in DLD-1 cells, and to 50.78% in SW620 cells upon Ad5CMVp53 infection; these increases in the CD95 expression, however, were not signi®cant compared to those previously reported for other cell lines. These results suggest that, despite p53 inactivation, H1299, DLD-1, and SW620 cells constitutively expressed a large amount of the CD95 receptor.
Up-regulation of CD95-L mRNA expression by Ad5CMVp53 infection
H1299, DLD-1, and SW620 cells were analysed for CD95-L mRNA expression by a semi-quantitative RT ± PCR assay. As shown in Figure 4a , a basal expression of CD95-L mRNA transcript was detected in parental H1299, DLD-1, and SW620 cells; CD95-L mRNA, however, was highly elevated upon infection with Ad5CMVp53. Maximal induction was achieved at 24 h after Ad5CMVp53 infection, followed by a rapid decrease. An up-regulation of CD95-L mRNA was not produced in any cell lines by control Ad5RSVLuc infection. Densitometric analysis of the sample band normalized to b-actin revealed that Ad5CMVp53 resulted in a 20-fold, ®vefold, and sevenfold increase of CD95-L mRNA levels in three cell lines, respectively, at 24 h after infection, compared to the mock-infected cells (Figure 4b ). To generate linear dilution curves for quantitation of CD95-L mRNA expression, RT products were sirially diluted and then analysed by PCR for 27 cycles ( Figure 4c ). As shown in Figure 4d , the relation between the dilution and the signal strength of the ampli®ed product was reprodicibly almost linear for all three cell lines. Additionally, to test whether the CD95-L mRNA expression was accompanied by CD95-L protein expression, a¯ow cytometric analysis was performed for cell surface expression of CD95-L. To prevent the cleavage of the cell-surfece CD95-L, H1299, DLD-1, and SW620 cells were exposed to Ad5CMVp53 in the presence of metalloprotease inhibitor. Ad5CMVp53 infection caused a moderate up-regulation of CD95-L protein in all three cell lines, whereas the mock-infected cells were almost negative (Figure 4e ).
Sensitivity of CD95-positive cells to anti-CD95 antibody-mediated apoptosis
To functionally assess the CD95 receptor expression on H1299, DLD-1, and SW620 cells, we performed a cytotoxic assay using an anti-CD95 monoclonal antibody (CH11). Cells were cultured in the presence of the anti-CD95 antibody or an isotype-matched control antibody over a period of 72 h. Agonistic stimulation with the anti-CD95 antibody led to a rapid loss of cell viability in up to 65% of the H1299 cells, whereas the DLD-1 and SW620 cells did not respond to the treatment ( Figure 5a ). As expected, CD95-transfected WR19L-12a cells were highly sensitive to anti-CD95 treatment, and the WR19L cells lacking CD95 expression were unaected by the anti-CD95 antibody. To obtain further details of the dierential sensitivity to agonistic CD95 stimulation, H1299 and DLD-1 cells were treated with either Ad5CMVp53 or anti-CD95 antibody, stained with the DNA intercalating dye Hoechst 33342, and then examined in ā uorescence microscopy analysis. Both H1299 and DLD-1 cells underwent apoptosis, which was characterized by highly condensed and partially fragmented nuclei, after infection with Ad5CMVp53 (30 MOI); only H1299 cells, however, demonstrated apoptotic cell death following anti-CD95 treatment (Figure 5b ). Unaltered nuclei were observed in both cell lines treated with Ad5RSVLuc at a MOI of 30. These results revealed that tumor cell lines that are sensitive to p53-mediated apoptosis might dierentially respond to the agonisitic anti-CD95 stimulation despite their approximately equal CD95 receptor expressions.
Dierential inhibition of Ad5CMVp53-induced apoptosis by blocking of CD95/CD95-L interaction
Finally, to directly determine whether the CD95 receptor/ligand system is involved in the p53-mediated apoptotic pathway, we employed an anti-CD95-L blocking antibody (4H9) that can interfere with the CD95 receptor/ligand interaction. The results of the blocking experiments for H1299, DLD-1, and SW620 cell lines are illustrated in Figure 6 . The pretreatment of H1299 cells with antagonistic anti-CD95-L antibody partially, but signi®cantly, inhibited the Ad5CMVp53-triggered apoptosis after 24 h of infection (P50.01). In contrast, the blocking of the CD95 receptor/ligand engagement by the antibody did not aect the apoptotic cell death induced by wt-p53 transduction in the DLD-1 and SW620 cells. These data show that the apoptosis induced by the wt-p53 gene transfer might be partially mediated via CD95 signaling; the CD95 pathway, however, might be an accessory rather than the main pathway.
Discussion
The introduction of the wt-p53 gene is a powerful inducer of apoptosis in certain types of human cancer cells despite their diering p53 status. The p53 protein is known to be a transcription factor that regulates the rate of transcription of other genes either positively or negatively. Some of these genes are known to be essential for triggering apoptosis, but the downstream events mediated by p53 are not well understood. It was reported that local tumor regression was produced by replication-defective retrovirus-mediated wt-p53 gene transfer in three of nine NSCLC patients who had not responded to conventional therapies (Roth et al., 1996) . Frequent apoptotic cell death was observed in these patients' post-treatment biopsy specimens, suggesting that p53-mediated apoptosis might have played a signi®cant role in the therapeutic responses.
To gain further insight into the mechanism of p53-mediated apoptosis, we investigated whether the CD95 receptor/ligand system is involved in the apoptotic pathway initiated by wt-p53 gene transduction. H1299, DLD-1, and SW620 are human cancer cell lines of dierent tissue origin, all of which are sensitive to p53-mediated apoptosis. Our preliminary experiments using an adenovirus vector encoding a bgalactosidase reporter gene revealed that the ecacy of viral infection as well as that of transgene expression did not vary between these three cell lines. Although human NSCLC H226Br cells could be easily transduced with the wt-p53 gene by an adenovirus vector, the fate of transduced H226Br cells is limited to growth suppression rather than apoptosis, suggesting that the cell types in¯uence the decision of a cell to enter a p53-mediated cell cycle arrest or apoptotic cell death. a b Figure 5 Cytotoxic response of H1299, DLD-1, and SW620 cell lines to anti-CD95 monoclonal antibody (CH11). (a) Cultured cells were treated with 1 mg/ml of anti-CD95 antibody (CH11) for 72 h. Viable cell recovery was determined by cell counting. CD95-expressing WR19L-12a cells and parental WR19L cells were used as a positive and negative control, respectively. The mean+standard deviation of three dierent wells is shown. (b) Morphological analysis of H1299 and DLD-1 cells treated with either Ad5CMVp53 or CH11. Cells were infected with Ad5CMVp53 vector at 30 MOI or treated with 1 mg/ml of anti-CD95 antibody (CH11) for 72 h. Cells were stained with Hoechst 33342 and analysed under a¯uorescence microscope Therefore, we employed H1299, DLD-1, and SW620 cells for our in vitro experiments to investigate the p53-activated apoptotic machinery.
CD95-L is constitutively expressed in some normal organs, such as the testis, eye, certain epithelial cells, and neurons, as well as a number of neoplastic cells; H1299, DLD-1 and SW620 cells, however, show a basal expression of CD95-L mRNA. We found that all of three cell lines showed a transient CD95-L upregulation following ectopic wt-p53 gene transfer. A time-course experiment demonstrated that the CD95-L mRNA levels increased as early as 24 h after infection followed by a signi®cant decrease over a period of 36 h, which was consistent with a rapid induction of apoptosis within 24 h. Elevated CD95-L mRNA levels correlated well with the cell-surface CD95-L protein expression, although intense mRNA expression may not always be accompanied by protein increase. Anticancer drugs including doxorubicin, bleomycin, cisplatinum, and VP-16 were recently shown to induce CD95-L production in some tumor cell lines (Fuluda et al., 1997) . Muller et al. (1997) observed a drug-induced CD95-L up-regulation in hepatoma cells carrying wtp53, while mutant p53-expressing hepatoma cells did not respond to drug treatment. Our results are compatible with these ®ndings, because p53 protein is known to accumulate upon treatment with DNAdamaging anticancer agents. Although the precise mechanism responsible for the p53-mediated induction of CD95-L remains to be elucidated by further investigations, the promoter region of the CD95-L gene contains sequence-speci®c binding elements for transcriptional factors such as nuclear factor-kB and interferon regulatory factor-1 (Ivanov et al., 1997) . Additionally, CD95-L mRNA expression is upregulated as early as 12 h after wt-p53 gene transfer in H1299 cells. Therefore, although the results must be con®rmed by the transcriptional assay, it is likely that the introduction of the wt-p53 gene directly induce CD95-L expression.
CD95 receptor expression is widely distributed among tumors of various histological types; the susceptibility of cells to apoptosis induced by CD95 stimulation, however, is not correlated with the expression levels of this protein (Owen-Schaub et al., 1994) . In accordance with these observations, the biological eects of agonistic anti-CD95 (CH11) engagement diered between the H1299 and DLD-1 cell lines expressing equivalent levels of cell surface CD95:anti-CD95 (CH11) caused apoptosis in H1299 cells, but not in DLD-1 cells. In addition to these results, it has been con®rmed that an antagonistic anti-CD95-L antibody (4H9) incompletely, but signi®cantly, inhibited apoptosis induced by wt-p53 gene transduction in H1299 cells, whereas anti-CD95-L did not aect p53-triggered apoptosis in DLD-1 cells. Thus, the CD95 receptor/ligand system may be dierentially and partially involved in the p53-mediated apoptotic pathway. The data obtained by Muller et al. and Fulda et al. which showed that drug-induced apoptosis was almost completely inhibited by F(ab)' 2 -anti-CD95 antibody fragments, suggest a general role of the CD95 receptor/ligand system for cytotoxicity by anticancer drugs (Muller et al., 1997; Fuluda et al., 1997) . One possible explanation for the discrepancy of the results is due to the dierences of tumor cell types and/or experimental systems (e.g., intrinsic p53 induction vs ectopic p53 overexpression). Our data, at least, provide evidence that p53-mediated apoptosis may use a major alternative pathway, which is independent of the CD95 receptor/ligand system. Fuchs et al. have demonstrated that p53-dependent DNA damage-induced apoptosis requires CD95-independent activation of CPP32b, a member of the caspase family of cysteine proteases that are essential for apoptotic cell death (Fuchs et al., 1997) . In addition, it has recently been reported that KILLER/DR5, which is a receptor protein of CD95-like death-inducing ligand TRAIL, may be responsible for p53-dependent cell death machinery (Wu et al., 1997) . Further studies are required to dissect the major determinants of p53-triggered responses. Experiments to determine whether a neutralizing TRAIL antibody could inhibit p53-mediated apoptosis are underway in our laboratory.
Molecular analyses of apoptosis has revealed a number of gene products that regulate the cell death process, such as the family of interleukin 1b-converting enzyme (ICE)-like proteases, which are now designated as caspases (Seamus and Green, 1995) . Signaling by means of CD95 is known to trigger the caspase cascade, leading to apoptotic cell death. It is likely that the activation of the caspase family is also involved in p53-mediated apoptosis, as evidenced by our preliminary ®nding that the overexpression of the wt-p53 gene could cleave the death substrate of caspases, poly(ADP)ribose polymerase, in DLD-1 cells (T Yamatsuji and T Fujiwara, unpublished data). These observations indicate that the upstream events for CD95 signaling may be blocked in DLD-1 cells and that p53 could directly trigger caspase activation through the alternative mechanism. Recent studies have identi®ed several molecules related to CD95 signal transduction. Yanagisawa et al. (1997) reported that Fas-associated phosphatase-1 (FAP-1) bound to the negative regulatory domain of CD95, leading to the inhibition of CD95-induced apoptosis in DLD-1 cells. This ®nding suggests that the very ®rst step of CD95 signaling is blocked by FAP-1 in DLD-1 cells. Thus, further experiments targeting downstream signal transduction are required to elucidate which molecule is directly activated in p53-mediated apoptosis.
We have demonstrated a gain of CD95-L expression due to the overexpression of the wt-p53 gene and the dierential involvement of the CD95 receptor/ligand system in p53-mediated apoptosis. These ®ndings suggest that multiple pathways leading to apoptosis, including CD95-dependent and CD95-independent mechanisms, could be initiated by an ectopic p53 gene transfer. We previously demonstrated that p53 overexpression can be a powerful inducer of apoptosis even in cell cycle-arrested tumor cells (Kagawa et al., 1997) . These results, taken together, indicate that the wt-p53 gene transfer may be potentially useful for gene-based anticancer therapy. In addition, it was recently reported that CD95-L expression in tumor cells stimulated a dense neutrophilic in®ltration that caused tumor destruction in vivo (Arai et al., 1997) . In a transplantation model, Kang et al. showed massive neutrophilic in¯ammation associated with CD95-L expression in pancreatic b cell transplants (Kang et al., 1997) . Increased CD95-L expression by p53 may not be essential for a CD95-mediated self-killing mechanism in certain tumor cells with an inactive CD95 signaling pathway (e.g., DLD-1); CD95-L-induced neutrophilic in®ltration, however, may accelerate the destruction of neighboring tumor cells that were not transduced with wt-p53. Thus, the p53-mediated up-regulation of CD95-L is likely to provide further insights for the molecular basis of the bystander eect. In conclusion, p53 gene therapy could be a useful molecular intervention for human malignancies by generating potent apoptotic and in¯ammatory antitumor responses.
Materials and methods
Cells and culture conditions
The human NSCLC cell line, H1299, which has homozygously deleted p53, and the human colon carcinoma cell lines, DLD-1 and SW620, which exhibit a homogygous p53 gene mutation, were maintained in monolayer cultures in 75-cm 2 tissue culture¯asks. The mouse T-cell leukemia line, WR19L, that was stably transfected with human CD95 cDNA (WR19L-12a) was the generous gift of Dr Shin Yonehara (Biomedical Institute, Osaka, Japan). The mouse T-cell leukemia line L5178Y stably expressing human CD95-L (hFAS-L/L5178Y) was provided by Dr Hideo Yagita (Department of Immunology, Juntendo University, School of Medicine, Tokyo, Japan). These cell lines were routinely propagated in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), 25 mM HEPES, 100 units/ml penicillin and 100 mg/ml streptomycin. The transformed embryonic kidney cell line 293 was grown in Dulbecco's-modi®ed Eagle's Medium (D-MEM) (Gibco, Grand Island, NY, USA) with high glucose (4.5 g/l), supplemented with 10% FCS, 100 units/ml penicillin and 100 mg/ml streptomycin.
Recombinant adenoviruses
The recombinant adenovirus vector expressing human wtp53 cDNA was previously constructed and characterized (Zhang et al., 1994; Fujiwara et al., 1994) . The resultant virus was named Ad5CMVp53. An adenoviral vector containing luciferase cDNA (Ad5RSVLuc) was used as a control vector. The viral stocks were quanti®ed by a plaque-forming assay using 293 cells and stored at 7808C.
Detection of transduced wt-p53 gene expression
Total RNA was isolated from mock-, Ad5RSVLuc-, and Ad5CMVp53-infected cells using RNAzol (Cinna/Bio Tecx, Friendswood, TX, USA) in a single-step phenolextraction method and used as templates. Reverse transcription was performed at 228C for 10 min and then 428C for 20 min using 1.0 mg of RNA per reaction to ensure that the amount of ampli®ed DNA was proportional to that of speci®c mRNA in the original sample. PCR was performed with speci®c primers in volumes of 50-ml according to the manufacturer's protocol (PCR kit; Perkin-Elmer/Cetus, Norwalk, CT, USA). The speci®c primers used for the CMV promoter/ p53 region of Ad5CMVp53 were CMV3 (5'-GGT GCA TTG GAA CGC GGA TT-3') and Rev Ex3 (5'-CAA ATC ATC CAT TGC TTG GGA-3'). The primers for GAPDH were GAPDH-S (5'-CAG CCG AGC CAC ATC-3') and GAPDH-AS (5'-TGA GGC TGT TGT CAT ACT TCT-3'). The ampli®cation reaction involved denaturation at 928C for 1 min, annealing at 588C for 1 min and 728C for 1 min using a thermal cycler (PerkinElmer, Foster City, CA, USA). The PCR products were resolved on 1% agarose gels and visualized by ethidium bromide staining.
Immunohistochemistry
Immunohistochemical staining was performed using a HISTOFINE kit (Nichirei, Tokyo, Japan). The slides were blocked with 1% BSA for 30 min and incubated with the primary antibody overnight at 48C in a highhumidity chamber. After a rinsing, the slides were incubated with biotinylated rabbit anti-mouse immunoglobulin G for 10 min and then with avidin-biotin-peroxidase complex for 10 min. Peroxidase activity was detected using 3, 3'-diamino-benzidine tetrahydrochloride solution containing 0.003% hydrogen peroxide. Slides were counterstained with methylgreen. The primary antibodies used were anti-p53 and anti-p21/WAF1 (Ab-1) antibodies (Oncogene Science, Manhasset, NY, USA). Negative control slides were processed with mouse preimmune immunoglobulin.
Flow cytometric detection of apoptosis
Trypsinized adherent and¯oating cells were collected, washed twice with cold phosphate-buered saline (PBS), and resuspended in PBS containing 0.1% Triton X-100 and 1g/l RNase for 5 min at room temperature. Samples were then stained with propidium iodide at 50 mg/ml and analysed in a cell sorter (FACScan, Becton Dickinson, Mountain View, CA, USA) for DNA content. Cell debris and ®xation artifacts were gated out, and apoptosis was quanti®ed using the ModFit LT software program for Mac Ver. 1.01 (Verity Software House, Inc.).
Visualization of apoptotic nuclei
Tumor cells (1610 6 ) were grown on plastic cover slips and treated as described above. Cells were ®xed with 1.0% gluteraldehyde and stained with the DNA intercalating dye Hoechst 33342 (1 mM in PBS). Cells were then viewed and photographed with a¯uorescence microscope (Zeiss, Oberkochen, Germany).
Detection of CD95 receptor expression
The cell surface expression of the CD95 receptor was assessed by¯ow cytometric analysis. A¯uorescein isothiocyanate (FITC)-conjugated mouse anti-CD95 monoclonal antibody (UB-2) purchased from Medical and Biochemical Laboratories Co. (Nagoya, Japan) was used according to the manufacturer's recommendations. Brie¯y, 1610 6 cells were incubated with 1 mg of anti-CD95 or isotype-matched control antibody (DX-2: DAKO Corp., Carpinteria, CA) for 30 min at 48C. After being washed twice, the cells were analysed by the FACScan with the window set to exclude dead cells and debris, using CELL Quest software. Ten thousand cells were examined for each determination.
Detection of CD95-L expression by RT ± PCR
Total cellular RNA was prepared from cells using surfactant solution-Catrimox-14TM (Takara Biochemicals, Osaka, Japan). Reverse transcription-PCR was performed in the Perkin-Elmer thermal cycler according to the protocol described above for transduced wt-p53 detection. The primers used for the ampli®cation of CD95-L were CD95-L-S (5'-CAA GTC CAA CTC AAG GTC CAT GCC-3') and CD95-L-AS (5'-CAG AGA GAG CTC AGA TAC GTT TGA C-3'). The amounts of RNA used in the assay were veri®ed by the detection of the human bactin m-RNA by using speci®c primers (b-actin-S: 5'-TGA CGG GGT CAC CCA CAC TGT GCC CAT CTA-3'; bactin-AS: 5'-CTA GAA GCA TTT GCG GTG GAC GAT GGA GGG-3'). The density of PCR products visualized by ethidium bromide staining was quanti®ed using an image analyzing program, NIH Image, with b-actin as the internal control. Quantitative assessment was performed by comparing the ampli®ed signal intensity in serialy diluted RT products.
Detection of the cell-surface CD95-L expression by¯ow cytometreic analysis
The cell surface expression of the CD95-L was assessed bȳ ow cytometric analysis. A mouse anti-CD95-L monolonal antibody (NOK-1), which was kindly provided by Dr Hideo Yagita (Dept. of Immunology, Juntendo University School of Medicine, Tokyo), was used for a primary antibody. A FITC-conjugated rabbit anti-mouse IgG was used as a detecting reagent. Brie¯y, H1299, DLD-1 and SW620 cells were infected with Ad5CMVp53 in the presence of 10 mM of metaloprotease inhibitor to prevent the cleavage of the cell-surface CD95-L. Then, 1610 6 cells were incubated with 1 mg of anti-CD95-L or isotypematched control antibody for 30 min at 48C and then incubated with FITC-conjugated secondary antibody. After being washed twice, the cells were analysed by the FACScan with the window set to exclude dead cells and debris, using CELL Quest software. Ten thousand cells were examined for each determination.
Anti-CD95 antibody-mediated cytotoxicity Cells (5610 3 /well) were incubated in 96-well¯at-bottomed plates in triplicate in the presence of a murine IgM monoclonal antibody against human CD95 (CH11) (Medical and Biochemical Laboratories Co.) (1 mg/ml) for up to 72 h. Cellular viability was assessed by Trypan blue uptake. The percentage of viability was calculated by the following formula: 1006(total cell number recovered in the presence of CH11/total untreated cell number).
Blocking of the CD95 receptor/ligand system by anti-CD95-L antibody Cells (1610 4 well) were incubated in 96-well¯at-bottomed plates in triplicate and infected with either Ad5CMVp53 or Ad5RSVLuc in the presence of a hamster anti-CD95-L monoclonal antibody (4H9) (Medical and Biochemical Laboratories Co.) (5 mg/ml) for up to 24 h. Cellular viability was determined by Trypan blue staining. The statistical analysis was performed with Student's t-test. P50.05 was considered signi®cant.
Abbreviations IGF-BP, insulin-like growth factor-binding protein; CD95-L, CD95 ligand; CMV, cytomegalovirus; NSCLC, nonsmall cell lung cancer; MOI, multiplicity of infection; RT-PCR, reverse transcription-PCR; ICE, interleukin 1b-converting enzyme; FAP-1, Fas-associated phosphatase-1; FITC,¯uorescein isothiocyanate.
